“We currently see eight GLP-1s assets in the market. We’re covering six of those already, and we’re going to look to add as the market is evolving,” Sandoz has revealed, as it delved deeper into what it estimates is a near $60bn loss of exclusivity opportunity in the next decade.
Speaking during the firm’s recent Sandoz Strategic Review 2024 event in Zurich, Switzerland, Sandoz’s management underlined plans in the midterm to use a partnered approach to spring up early in developed non-US, non-EU markets
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Generics Bulletin for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?